Stephanie Lake

Stephanie Lake

Auto-generated profile, based on publicly available information

Stephanie Lake

Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2018 in Addiction
Verified
Journal Article
Closed access
PDF file
MSMaria Eugenia Socías
Maria Eugenia Socías
EWEvan Wood
Evan Wood
SLStephanie Lake
Stephanie Lake
SNSeonaid Nolan
Seonaid Nolan
NFNadia Fairbairn
Nadia Fairbairn
MMMichael John S. Milloy
Michael John S. Milloy


21 May 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SLStephanie Lake
Stephanie Lake
ENEkaterina Nosova
Ekaterina Nosova
JBJane Buxton
Jane Buxton
ZWZach Walsh
Zach Walsh
MSM Eugenia Socías
M Eugenia Socías
MMMichael John S. Milloy
Michael John S. Milloy
Cannabis use is common among marginalized people who use illicit drugs (PWUD) but reasons for use remain poorly investigated. We sought to explore how different intentions for cannabis use relate to social, structural, and behavioural factors among PWUD in Vancouver, Canada. We used data from cannabis-using participants in two community-recruited prospective cohort studies of PWUD. Using latent class analysis, we identified discrete cannabis-using groups based on self-reported intentions for use. Generalized estimating equations were used to examine correlates of class membership. Between June 2016 and December 2018, 2,686 observations from 897 participants cannabis-using PWUD were analyzed. Four latent classes of cannabis use emerged: Class 1 (31.6%), characterized by non-medical purposes; Class 2 (37.5%), characterized by non-pain therapeutic use (e.g., stress, nausea/loss of appetite, and insomnia); characterized by Class 3 (21.9%) predominantly pain relief; and Class 4 (9.0%), characterized by a wide range of therapeutic uses in addition to pain management, including insomnia, stress, nausea/loss of appetite, and harm reduction. Class-specific structural, substance-, and health-related differences were observed, including indicators of better physical and mental health among the “recreational” class, despite evidence of more structural vulnerabilities (e.g., homelessness, incarceration). Our findings demonstrate a wide spectrum of motivations for cannabis use among PWUD. We observed important health-related differences between latent classes, demonstrating possible unmet healthcare needs among PWUD reporting therapeutic cannabis use. These findings inform ongoing policy surrounding access to cannabis for harm reduction purposes and applications of medical cannabis for PWUD.

1 June 2023 in Psychedelic Medicine
Verified
Journal Article
Closed access
SLStephanie Lake
Stephanie Lake
PLPhilippe Lucas
Philippe Lucas
Background: : Recent years have seen a resurgence in clinical interest in, and increased public acceptance of, psychedelic drugs in Canada. However, our understanding of how psychedelic drugs are currently used in Canada remains limited. We developed the Canadian Psychedelic Survey (CPS) to gather real-world evidence about psychedelic drug use in Canada. This study aimed to characterize CPS respondents; identify access sources; explore psychedelic-specific patterns, purposes, and contexts of use; and contextualize intense positive and challenging psychedelic experiences. Methods: The CPS was administered in January 2022. We used descriptive statistics to characterize the sample and understand access to psychedelic drugs and detailed patterns and contexts of use. We built separate logistic regression models to identify sociodemographic and psychedelic-related correlates of reporting an intense positive and challenging experience with psychedelic drugs. Results: : We analyzed data from 2045 respondents (mean age = 38.4 years; 56% female). Psilocybin, 3,4-methylenedioxymethamphetamine (MDMA), and lysergic acid diethylamide (LSD) were the most used psychedelic drugs. Top motivations for psychedelic drug use were fun, self-exploration, general mental well-being, and personal growth. Lifetime intense positive and challenging psychedelic experiences were reported by 82% and 52%, respectively. Over half (56%) of those who had an intense challenging experience reported that “some good” came from the experience after-the-fact. In multivariable analysis, significant correlates of intense positive experiences included higher perceived psychedelic experience and fun and self-exploration as motivations for use ( p < 0.05). Significant correlates of intense challenging experiences included higher perceived psychedelic experience and trauma management, fun, and boredom as motivations for use ( p < 0.05). Conclusion: The CPS is the most comprehensive survey of psychedelic drug use to date. Detailing the range of therapeutic and nontherapeutic experiences of psychedelic drug consumers in Canada, these findings add important nuances that can inform evolving clinical research and policy discussions impacting safe access to and use of psychedelic drugs.

1 September 2019 in Drug and Alcohol Review
Verified
Journal Article
Closed access
PDF file
SLStephanie Lake
Stephanie Lake
TKThomas Kerr
Thomas Kerr
DWDan Werb
Dan Werb
RHRebecca Haines‐Saah
Rebecca Haines‐Saah
BFBenedikt Fischer
Benedikt Fischer
MMMichael John S. Milloy
Michael John S. Milloy

21 July 2023 in International Journal of Drug Policy
Verified
Journal Article
Closed access
HRHudson Reddon
Hudson Reddon
SLStephanie Lake
Stephanie Lake
MSMaria Eugenia Socias
Maria Eugenia Socias
KHKanna Hayashi
Kanna Hayashi
KDKora DeBeck
Kora DeBeck
MMM-J Milloy
M-J Milloy